Recurrent Urinary Tract Infection Clinical Trial
Official title:
Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections: a Multicenter, Randomized, Placebo-controlled Trial
The aim of this study was to initially evaluate the optimal dose, efficacy, and safety of vitamin D3 for reducing recurrence of recurrent urinary tract infections (rUTIs).
Urinary tract infection (UTI) is a multiple disease that ranks second only to respiratory infections in infectious diseases and is one of the most common infectious diseases among adults. After the first urinary tract infection, the probability of recurrence within half a year and within one year was as high as 24% and 70%, respectively. Urinary tract infection itself has the characteristics of easy recurrence, which is closely related to the abuse of antibiotics, the generation of bacterial resistance, and the decline of local immune function of mucosa. In the urinary tract, the antibacterial peptide Cathelicidin is mainly located in the proximal tubules of the kidney and the epithelial cells of the renal pelvis and ureter. LL37 is the only antibacterial peptide present in the human body of the Cathelicidin family, which can be regarded as a natural antibiotic produced by the body. Antibacterial peptides have a broad-spectrum antibacterial effect and can exert antibacterial effects against both Gram-positive and Gram-negative bacteria. Vitamin D intake increases the activity of endogenous antimicrobial peptides. Preclinical cell test of Zensun Sci. & Tech. Co., Ltd. confirmed the induction of LL37 in urethral epithelial cells by vitamin D and its broad-spectrum antibacterial effect. Animal experiments also showed the therapeutic effect of LL37 on UTI. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02357758 -
Effects of Antibiotic Prophylaxis on Recurrent UTI in Children
|
Phase 4 | |
Completed |
NCT04306731 -
Effect of Nanotechnology Structured Water Magnalife for the Prevention of Recurrent Urinary Tract Infections.
|
N/A | |
Recruiting |
NCT05553652 -
The Effect of ASTARTEā¢ on Recurrent Urinary Tract Infection
|
N/A | |
Completed |
NCT01958073 -
Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women
|
Phase 4 | |
Recruiting |
NCT05652374 -
Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study
|
Phase 4 | |
Recruiting |
NCT06124820 -
RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections
|
N/A | |
Recruiting |
NCT04807894 -
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
|
Phase 4 | |
Enrolling by invitation |
NCT04077580 -
The Effect of Methenamine Hippurate to Reduce Antibiotic Prescribing in Elderly Women With Recurrent UTI
|
Phase 4 | |
Terminated |
NCT03143920 -
Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder
|
Early Phase 1 | |
Terminated |
NCT04831840 -
Recurrent Urinary Tract Infections and the Microbiome
|
||
Withdrawn |
NCT03854396 -
Clinical Trial on the Preventive Effect of Intravaginal Prasterone on Recurrent Urinary Tract Infections in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT02705495 -
Acupuncture for Prevention of Recurrent Urinary Tract Infections.
|
N/A | |
Active, not recruiting |
NCT05537519 -
Phage Therapy for the Treatment of Urinary Tract Infection
|
Phase 1/Phase 2 | |
Recruiting |
NCT06035601 -
EHR-integrated rUTI Texting Platform
|
N/A | |
Not yet recruiting |
NCT04285320 -
Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections
|
Phase 4 | |
Recruiting |
NCT03142295 -
Controlled Human Urine Transfusion for UTI
|
N/A | |
Recruiting |
NCT05895578 -
Effect of a Probiotic on the Urinary Tract Microbiota of Participants With Recurrent Urinary Tract Infection.
|
N/A | |
Completed |
NCT00214045 -
Rigid Versus Flexible Cystoscopy in Women
|
N/A | |
Enrolling by invitation |
NCT05551949 -
Preventing Recurrent UTI With Vaginal Estrogen
|
Phase 4 | |
Recruiting |
NCT05472779 -
Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections
|
Phase 2 |